Bicara Therapeutics Inc. (BCAX:NASDAQ) closed at $17.91 on October 21, 2026, down 2.40% on the day. The stock trades 42.2% below its 52-week high of $30.99 and 30.7% above its 52-week low of $13.70. Over the past year, it gained 8.9%. Bicara Therapeutics Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, BCAX closed higher on 124 days (49%). Its best day was November 21, 2025 (+11.50%) and its worst was August 11, 2026 (-14.32%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025.
Find more stocks like BCAX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.